Aclarion (ACON) investor relations material

Executive summary

• Revenue for Q1 2026 increased 11.3% year-over-year to $21,140, driven by higher Nociscan report sales in the UK market.

• Net loss widened to $2.85 million from $2.04 million in Q1 2025, reflecting higher operating expenses across all categories.

• Gross margin improved to 17.7% from -23.6% year-over-year due to lower cost of revenue and favorable revenue mix.

• Cash and cash equivalents at quarter-end were $19.03 million, supporting at least 12 months of operations.

Financial highlights

• Operating expenses rose sharply: sales and marketing up 200%, R&D up 59%, and G&A up 79% year-over-year.

• Interest income increased to $133,035 from $42,163, reflecting higher cash balances.

• No penalties or settlements in Q1 2026, compared to $672,500 in Q1 2025.

• Net cash used in operating activities was $2.64 million; net cash provided by financing activities was $9.68 million.

Outlook and guidance

• Management expects continued revenue growth as more insurance payors are added and scan volumes increase.

• Operating expenses, especially in sales, marketing, and R&D, are expected to rise as the company expands trials and commercialization.

• Cash resources are projected to fund operations into the second half of 2027.